Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by Boston Children’s Hospital.
Recruitment status was  Active, not recruiting
Progeria Research Foundation
Information provided by:
Boston Children’s Hospital Identifier:
First received: January 22, 2007
Last updated: December 24, 2007
Last verified: December 2007